Clinical Trials
19 trialsNCT07472868 2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3 Not yet recruiting
NCT05161572 2025-06-18
NeoRacing
Fudan University
Phase 2 Terminated
NCT06662877 2024-10-29
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Sun Yat-sen University
Phase 2/3 Not yet recruiting
NCT01285557 2024-09-19
DIGEST
Taiho Oncology, Inc.
Phase 3 Terminated
NCT01845337 2023-05-12
TOFFEE
University of Edinburgh
Phase 2 Completed
NCT05813015 2023-04-14
Study of Comparing of With and Without Sequential Therapy of S-1
Zhejiang University
Phase 3 Recruiting
NCT02191566 2022-12-08
SOHUG
Kangbuk Samsung Hospital
Phase 2 Terminated
NCT05396326 2022-05-31
A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT05346874 2022-05-26
Neoadjuvant TACiE in Locally Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03904225 2021-06-23
Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT02564367 2021-04-29
S-1 adjuvant
AIO-Studien-gGmbH
Phase 1/2 Completed
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT04377048 2020-05-06
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
National Taiwan University Hospital
Phase 2 Unknown
NCT02347904 2019-11-18
SOX
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1 Completed
NCT02216149 2018-08-28
FluoHeart
Helsinki University Central Hospital
Phase 2 Terminated
NCT01918852 2018-03-14
SALTO
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT01704690 2017-04-07
Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer
Peking University
Phase 2/3 Terminated
NCT02867397 2016-08-15
Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
Disphar International B.V.
Phase 1 Completed
NCT01608646 2012-05-31
Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer
Xijing Hospital
Phase 2 Unknown